Results 51 to 60 of about 54,884 (249)

Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Frontiers in Immunology, 2021
During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have ...
Estéfani García-Ríos, Marcos Nuévalos, Francisco J. Mancebo, Pilar Pérez-Romero   +3 more
doaj   +1 more source

Gene Engineering T Cells with T-Cell Receptor for Adoptive Therapy

, 2022
AbstractPrior to clinical testing of adoptive T-cell therapy with T-cell receptor (TCR)-engineered T cells, TCRs need to be retrieved, annotated, gene-transferred, and extensively tested in vitro to accurately assess specificity and sensitivity of target recognition.
Kortleve, Dian, van Brakel, Mandy, Wijers, Rebecca, Debets, Reno, Hammerl, Dora   +4 more
openaire   +3 more sources

BMT4me En Español: Multisite Feasibility and Usability Testing of a Spanish‐Language mHealth Adherence Support App for Spanish‐Speaking Caregivers of Children After Hematopoietic Stem Cell Transplantation and Cancer Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Medication nonadherence during the first 100 days after pediatric hematopoietic stem cell transplantation (HSCT) and during oncology treatment increases risk for complications. BMT4me is a caregiver‐facing mobile health (mHealth) application providing medication reminders, symptom tracking, and note‐taking features to support ...
Micah A. Skeens, Madeline R. Peek, Bianca Franklin, Emre Sezgin, Melissa Beauchemin   +4 more
wiley   +1 more source

Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques. [PDF]

PLoS ONE, 2013
The adoptive transfer of antigen-specific effector T cells is being used to treat human infections and malignancy. T cell persistence is a prerequisite for therapeutic efficacy, but reliably establishing a high-level and durable T cell response by ...
Carolina Berger, Michael Berger, Brian C Beard, Hans-Peter Kiem, Theodore A Gooley, Stanley R Riddell   +5 more
doaj   +1 more source

TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma

Journal for ImmunoTherapy of Cancer, 2023
Background Adoptive cellular therapies with chimeric antigen receptor T cells have revolutionized the treatment of some malignancies but have shown limited efficacy in solid tumors such as glioblastoma and face a scarcity of safe therapeutic targets.
David M Kranz, Michael J White, Mao Li, Maximilian O Schaettler, Rupen Desai, Anthony Z Wang, Alexandra J Livingstone, Dale K Kobayashi, Andrew T Coxon, Jay A Bowman-Kirigin, Connor J Liu, Diane E Bender, Tanner M Johanns, Gavin P Dunn   +13 more
doaj   +1 more source

Tracking the T‐cell repertoire after adoptive therapy [PDF]

Clinical & Translational Immunology, 2017
In recent years, there has been increased interest in using immunotherapy to treat cancer. Adoptive T-cell therapy (ACT) involves the isolation and expansion of tumour-specific T cells in vitro. Large numbers of tumour-specific T cells are then infused back into cancer patients to provide a substantial ‘boost’ to anti-cancer immunity.
Watkins, Thomas S., Miles, John J.
openaire   +6 more sources

Childhood Acute Lymphoblastic Leukemia Survival in Western Kenya: Reduction in Early Deaths and Treatment Abandonment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background An earlier study on children diagnosed with acute lymphoblastic leukemia (ALL) at Moi Teaching and Referral Hospital (MTRH) in Kenya reported a low event‐free survival (EFS), excess treatment abandonment, and high induction mortality.
Gilbert Olbara, George Bogonko, Festus Njuguna, Sandra Langat, Martha Kipngetich, Dennis Njenga, Gertjan Johannes Kaspers, Terry Allen Vik   +7 more
wiley   +1 more source

Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy

Clinical & Translational Immunology, 2019
Objectives Clinical response to antibody‐based immunotherapies targeting checkpoint inhibitors is critically dependent on the tumor immune microenvironment (TIME).
David G Walker, Reshma Shakya, Beth Morrison, Michelle A Neller, Katherine K Matthews, John Nicholls, Corey Smith, Rajiv Khanna   +7 more
doaj   +1 more source

Bridging the Gap in Neuroblastoma Care: Consensus‐Based Statements With Recommendations for Improved Patient and Caregiver Experiences

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neuroblastoma's complex, heterogeneous biology poses significant diagnostic and therapeutic challenges, often requiring caregivers to absorb complex information and participate in time‐sensitive decisions. However, caregivers often feel unprepared to evaluate options.
Vickie Buenger, Joseph Bauer, Jennifer Diamond, Maggie Fader, Shae Hansen, Jacqueline M. Kraveka, Johanna Schoen, Amber Shearer, Dena Sherwood   +8 more
wiley   +1 more source

Principles of adoptive T cell cancer therapy [PDF]

Journal of Clinical Investigation, 2007
The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy.
openaire   +2 more sources